Avelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a realworld retrospective cohort study
Authors:
- I. V. TsimafeyeuI. V. Tsimafeyeu
- O. V. BaklanovaOBO. V. Baklanova
- V. A. ChubenkoVCV. A. Chubenko
- A. S. KalpinskiyAKA. S. Kalpinskiy
- S. Z. SafinaSSS. Z. Safina
- A. A. LebedinetsALA. A. Lebedinets
- V. V. PetkauVPV. V. Petkau
- A. S. OlshanskayaAOA. S. Olshanskaya
- I. V. MyslevtsevIMI. V. Myslevtsev
- R. A. ZukovRZR. A. Zukov
Open Access
- 22 January 2025
- journal article
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 9-17
Abstract
Background: Immunotherapy-based regimens, such as nivolumab plus ipilimumab (Nivo-Ipi) and avelumab plus axitinib (Ave-Axi), are standard first-line treatments for metastatic clear-cell renal cell carcinoma (mRCC) with intermediate or poor IMDC risk. Comparative real-world evidence for these regimens remains limited.Methods: This retrospective cohort study included 102 patients with mRCC treated with Nivo-Ipi (n = 51) or AveAxi (n = 51) from 2018 to 2023. Propensity score matching was used to balance baseline characteristics, including IMDC risk and comorbidities. Primary endpoints were the rate of treatment-related adverse events (TRAEs) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and overall survival (OS).Results: Patient characteristics were balanced across cohorts, with a median age of 63.4 years, 76 % male, and 61 % having chronic cardiovascular diseases. The rate of any grade TRAEs was similar between Nivo-Ipi and Ave-Axi (62.7 % vs. 68.6 %, respectively), as was the rate of grade ≥ 3 TRAEs (11.7 % vs. 17.6 %). Patients treated with Ave-Axi had a significantly extended PFS (15.0 vs 9.7 months; p 0,05). The median OS was not reached.Conclusions: Nivo-Ipi and Ave-Axi are effective and well-tolerated first-line therapies for mRCC in real-world settings. Ave-Axi was associated with a significantly longer PFS and a numerically higher ORR compared to Nivo-Ipi.Keywords
This publication has 26 references indexed in Scilit:
- Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective studyInternational Journal of Clinical Oncology, 2024
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialAnnals of Oncology, 2024
- Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101ESMO Open, 2023
- Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumabUrologic Oncology: Seminars and Original Investigations, 2023
- 1465P Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) in the United StatesAnnals of Oncology, 2022
- The Distribution of Metastatic Renal Cell Carcinoma by Presenting Tumor Stage in the Modern EraClinical Genitourinary Cancer, 2022
- Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registryCancer Reports, 2020
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2019
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2018
- Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 RegistryClinical Genitourinary Cancer, 2017